What is the Fiscal Year for Biodexa Pharmaceuticals?
Date: November 13, 2026
Biodexa Pharmaceuticals's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Cardiff, Cardiff
Industry
Biotechnology Research
Stock Symbol
BDRX
Description
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers. The company’s lead development programme, eRapa, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is bowel resection. Without effective treatment virtually all FAP patients progress to develop colorectal cancer. The company is also working on treatments for type 1 diabetes and primary and metastatic cancers of the brain.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Biodexa Pharmaceuticals and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.